Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Engineering HSV-1 Vectors for Gene Therapy.

Goins WF, Huang S, Hall B, Marzulli M, Cohen JB, Glorioso JC.

Methods Mol Biol. 2020;2060:73-90. doi: 10.1007/978-1-4939-9814-2_4.

PMID:
31617173
2.

Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment.

Denton NL, Chen CY, Hutzen B, Currier MA, Scott T, Nartker B, Leddon JL, Wang PY, Srinivas R, Cassady KA, Goins WF, Cripe TP.

Mol Ther Oncolytics. 2018 Oct 18;11:62-74. doi: 10.1016/j.omto.2018.10.001. eCollection 2018 Dec 21.

3.

The effect of herpes simplex virus vector-mediated gene therapy of protein phosphatase 1α on bladder overactivity and nociception.

Majima T, Mori K, Kadekawa K, Takai S, Funahashi Y, Reinhart B, Goins WF, Gotoh M, Glorioso JC, Yoshimura N.

Neurourol Urodyn. 2019 Feb;38(2):582-590. doi: 10.1002/nau.23882. Epub 2018 Nov 29.

PMID:
30499116
4.

A Novel Oncolytic Herpes Simplex Virus Design based on the Common Overexpression of microRNA-21 in Tumors.

Marzulli M, Mazzacurati L, Zhang M, Goins WF, Hatley ME, Glorioso JC, Cohen JB.

J Gene Ther. 2018 Oct;3(1). doi: 10.13188/2381-3326.1000007. Epub 2018 Oct 18.

5.

Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System.

Artusi S, Miyagawa Y, Goins WF, Cohen JB, Glorioso JC.

Diseases. 2018 Aug 14;6(3). pii: E74. doi: 10.3390/diseases6030074. Review.

6.

Corrigendum to 'Morphological Changes in Different Populations of Bladder Afferent Neurons Detected by Herpes Simplex Virus (HSV) Vectors with Cell-type-specific Promoters in Mice with Spinal Cord Injury' [Neuroscience 364 (2017) 190-201].

Shimizu N, Doyal MF, Goins WF, Kadekawa K, Wada N, Kanai AJ, de Groat WC, Hirayama A, Uemura H, Glorioso JC, Yoshimura N.

Neuroscience. 2018 Jun 15;381:161. doi: 10.1016/j.neuroscience.2018.04.021. Epub 2018 Apr 26. No abstract available.

7.

Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.

Nakashima H, Nguyen T, Kasai K, Passaro C, Ito H, Goins WF, Shaikh I, Erdelyi R, Nishihara R, Nakano I, Reardon DA, Anderson AC, Kuchroo V, Chiocca EA.

Clin Cancer Res. 2018 Jun 1;24(11):2574-2584. doi: 10.1158/1078-0432.CCR-17-2954. Epub 2018 Mar 6.

8.

Effects of herpes simplex virus vectors encoding poreless TRPV1 or protein phosphatase 1α in a rat cystitis model induced by hydrogen peroxide.

Takai S, Majima T, Reinhart B, Goins WF, Funahashi Y, Gotoh M, Tyagi P, Glorioso JC, Yoshimura N.

Gene Ther. 2018 Jan;25(1):20-26. doi: 10.1038/gt.2017.94. Epub 2017 Oct 20.

9.

Morphological changes in different populations of bladder afferent neurons detected by herpes simplex virus (HSV) vectors with cell-type-specific promoters in mice with spinal cord injury.

Shimizu N, Doyal MF, Goins WF, Kadekawa K, Wada N, Kanai AJ, de Groat WC, Hirayama A, Uemura H, Glorioso JC, Yoshimura N.

Neuroscience. 2017 Nov 19;364:190-201. doi: 10.1016/j.neuroscience.2017.09.024. Epub 2017 Sep 20. Erratum in: Neuroscience. 2018 Apr 25;:.

10.

Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes.

Miyagawa Y, Verlengia G, Reinhart B, Han F, Uchida H, Zucchini S, Goins WF, Simonato M, Cohen JB, Glorioso JC.

Mol Ther Methods Clin Dev. 2017 Jun 16;6:79-90. doi: 10.1016/j.omtm.2017.06.001. eCollection 2017 Sep 15.

11.

MnSOD mediated by HSV vectors in the periaqueductal gray suppresses morphine withdrawal in rats.

Iida T, Yi H, Liu S, Ikegami D, Zheng W, Liu Q, Takahashi K, Kashiwagi Y, Goins WF, Glorioso JC, Hao S.

Gene Ther. 2017 May;24(5):314-324. doi: 10.1038/gt.2017.22. Epub 2017 Apr 3.

PMID:
28368370
12.

Retargeting of herpes simplex virus (HSV) vectors.

Goins WF, Hall B, Cohen JB, Glorioso JC.

Curr Opin Virol. 2016 Dec;21:93-101. doi: 10.1016/j.coviro.2016.08.007. Epub 2016 Sep 8. Review.

13.

An HSV-based library screen identifies PP1α as a negative TRPV1 regulator with analgesic activity in models of pain.

Reinhart B, Goins WF, Harel A, Chaudhry S, Goss JR, Yoshimura N, de Groat WC, Cohen JB, Glorioso JC.

Mol Ther Methods Clin Dev. 2016 Jun 22;3:16040. doi: 10.1038/mtm.2016.40. eCollection 2016.

14.

Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.

Nakashima H, Kaufmann JK, Wang PY, Nguyen T, Speranza MC, Kasai K, Okemoto K, Otsuki A, Nakano I, Fernandez S, Goins WF, Grandi P, Glorioso JC, Lawler S, Cripe TP, Chiocca EA.

J Clin Invest. 2015 Nov 2;125(11):4269-80. doi: 10.1172/JCI80713. Epub 2015 Oct 20.

15.

Herpes Simplex Virus Vector-Mediated Gene Delivery of Poreless TRPV1 Channels Reduces Bladder Overactivity and Nociception in Rats.

Majima T, Funahashi Y, Takai S, Goins WF, Gotoh M, Tyagi P, Glorioso JC, Yoshimura N.

Hum Gene Ther. 2015 Nov;26(11):734-42. doi: 10.1089/hum.2015.026. Epub 2015 Aug 31.

16.

Current gene therapy using viral vectors for chronic pain.

Guedon JM, Wu S, Zheng X, Churchill CC, Glorioso JC, Liu CH, Liu S, Vulchanova L, Bekker A, Tao YX, Kinchington PR, Goins WF, Fairbanks CA, Hao S.

Mol Pain. 2015 May 13;11:27. doi: 10.1186/s12990-015-0018-1. Review.

17.

Neuronal changes induced by Varicella Zoster Virus in a rat model of postherpetic neuralgia.

Guedon JM, Yee MB, Zhang M, Harvey SA, Goins WF, Kinchington PR.

Virology. 2015 Aug;482:167-80. doi: 10.1016/j.virol.2015.03.046. Epub 2015 Apr 11.

18.

Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity.

Miyagawa Y, Marino P, Verlengia G, Uchida H, Goins WF, Yokota S, Geller DA, Yoshida O, Mester J, Cohen JB, Glorioso JC.

Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):E1632-41. doi: 10.1073/pnas.1423556112. Epub 2015 Mar 16.

19.

Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity.

Leddon JL, Chen CY, Currier MA, Wang PY, Jung FA, Denton NL, Cripe KM, Haworth KB, Arnold MA, Gross AC, Eubank TD, Goins WF, Glorioso JC, Cohen JB, Grandi P, Hildeman DA, Cripe TP.

Mol Ther Oncolytics. 2015 Jan 21;1:14010. doi: 10.1038/mto.2014.10. eCollection 2015.

20.

Interferon-stimulated gene 15 (ISG15) and ISG15-linked proteins can associate with members of the selective autophagic process, histone deacetylase 6 (HDAC6) and SQSTM1/p62.

Nakashima H, Nguyen T, Goins WF, Chiocca EA.

J Biol Chem. 2015 Jan 16;290(3):1485-95. doi: 10.1074/jbc.M114.593871. Epub 2014 Nov 26.

21.

Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV.

Mazzacurati L, Marzulli M, Reinhart B, Miyagawa Y, Uchida H, Goins WF, Li A, Kaur B, Caligiuri M, Cripe T, Chiocca EA, Amankulor N, Cohen JB, Glorioso JC, Grandi P.

Mol Ther. 2015 Jan;23(1):99-107. doi: 10.1038/mt.2014.177. Epub 2014 Sep 9. Erratum in: Mol Ther. 2015 Jan;23(1):215. Chiocca, Nino [corrected to Chiocca, Ennio A].

22.

Relief of pain induced by varicella-zoster virus in a rat model of post-herpetic neuralgia using a herpes simplex virus vector expressing enkephalin.

Guedon JM, Zhang M, Glorioso JC, Goins WF, Kinchington PR.

Gene Ther. 2014 Jul;21(7):694-702. doi: 10.1038/gt.2014.43. Epub 2014 May 15.

23.

Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013.

O'Reilly M, Federoff HJ, Fong Y, Kohn DB, Patterson AP, Ahmed N, Asokan A, Boye SE, Crystal RG, De Oliveira S, Gargiulo L, Harper SQ, Ikeda Y, Jambou R, Montgomery M, Prograis L, Rosenthal E, Sterman DH, Vandenberghe LH, Zoloth L, Abedi M, Adair J, Adusumilli PS, Goins WF, Gray J, Monahan P, Popplewell L, Sena-Esteves M, Tannous B, Weber T, Wierda W, Gopal-Srivastava R, McDonald CL, Rosenblum D, Corrigan-Curay J.

Hum Gene Ther. 2014 Jun;25(6):488-97. doi: 10.1089/hum.2014.045. Review.

24.

Engineering HSV-1 vectors for gene therapy.

Goins WF, Huang S, Cohen JB, Glorioso JC.

Methods Mol Biol. 2014;1144:63-79. doi: 10.1007/978-1-4939-0428-0_5.

PMID:
24671677
25.

Progress in gene therapy for neurological disorders.

Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, Gray SJ, Lowenstein PR, Vandenberghe LH, Wilson TJ, Wolfe JH, Glorioso JC.

Nat Rev Neurol. 2013 May;9(5):277-91. doi: 10.1038/nrneurol.2013.56. Epub 2013 Apr 23. Review. Erratum in: Nat Rev Neurol. 2013 Jun;9(6):298.

26.

VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.

Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JL, Baird WH, Haseley A, Streby KA, Wang PY, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TP.

Mol Ther. 2013 May;21(5):1014-23. doi: 10.1038/mt.2013.39. Epub 2013 Mar 12.

27.

Effects of herpes simplex virus vector-mediated enkephalin gene therapy on bladder overactivity and nociception.

Yokoyama H, Oguchi T, Goins WF, Goss JR, Nishizawa O, de Groat WC, Wolfe D, Krisky DM, Glorioso JC, Yoshimura N.

Hum Gene Ther. 2013 Feb;24(2):170-80. doi: 10.1089/hum.2011.180. Epub 2013 Feb 14.

28.

Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV.

Wang PY, Currier MA, Hansford L, Kaplan D, Chiocca EA, Uchida H, Goins WF, Cohen JB, Glorioso JC, van Kuppevelt TH, Mo X, Cripe TP.

Gene Ther. 2013 Jul;20(7):761-9. doi: 10.1038/gt.2012.93. Epub 2012 Dec 20.

29.

Herpes simplex virus vector mediated gene therapy of tumor necrosis factor-α blockade for bladder overactivity and nociception in rats.

Funahashi Y, Oguchi T, Goins WF, Gotoh M, Tyagi P, Goss JR, Glorioso JC, Yoshimura N.

J Urol. 2013 Jan;189(1):366-73. doi: 10.1016/j.juro.2012.08.192. Epub 2012 Nov 19.

PMID:
23174234
30.

Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.

Uchida H, Marzulli M, Nakano K, Goins WF, Chan J, Hong CS, Mazzacurati L, Yoo JY, Haseley A, Nakashima H, Baek H, Kwon H, Kumagai I, Kuroki M, Kaur B, Chiocca EA, Grandi P, Cohen JB, Glorioso JC.

Mol Ther. 2013 Mar;21(3):561-9. doi: 10.1038/mt.2012.211. Epub 2012 Oct 16.

31.

Quantification of HSV-1-mediated expression of the ferritin MRI reporter in the mouse brain.

Iordanova B, Goins WF, Clawson DS, Hitchens TK, Ahrens ET.

Gene Ther. 2013 Jun;20(6):589-96. doi: 10.1038/gt.2012.70. Epub 2012 Sep 20.

32.

Gene therapy for the treatment of chronic peripheral nervous system pain.

Goins WF, Cohen JB, Glorioso JC.

Neurobiol Dis. 2012 Nov;48(2):255-70. doi: 10.1016/j.nbd.2012.05.005. Epub 2012 Jun 2. Review.

33.

Effect of herpes simplex virus vector-mediated interleukin-4 gene therapy on bladder overactivity and nociception.

Oguchi T, Funahashi Y, Yokoyama H, Nishizawa O, Goins WF, Goss JR, Glorioso JC, Yoshimura N.

Gene Ther. 2013 Feb;20(2):194-200. doi: 10.1038/gt.2012.24. Epub 2012 Mar 8.

PMID:
22402319
34.

Varicella zoster virus-induced pain and post-herpetic neuralgia in the human host and in rodent animal models.

Kinchington PR, Goins WF.

J Neurovirol. 2011 Dec;17(6):590-9. doi: 10.1007/s13365-011-0069-7. Epub 2011 Dec 28.

35.

Generation of replication-competent and -defective HSV vectors.

Goins WF, Krisky DM, Wechuck JB, Wolfe D, Huang S, Glorioso JC.

Cold Spring Harb Protoc. 2011 May 1;2011(5):pdb.prot5615. doi: 10.1101/pdb.prot5615.

PMID:
21536761
36.

Single chain ferritin chimera as an improved MRI gene reporter.

Iordanova B, Robison CS, Goins WF, Ahrens ET.

Prilozi. 2010;31(2):151-5.

37.

HSV delivery of a ligand-regulated endogenous ion channel gene to sensory neurons results in pain control following channel activation.

Goss JR, Cascio M, Goins WF, Huang S, Krisky DM, Clarke RJ, Johnson JW, Yokoyama H, Yoshimura N, Gold MS, Glorioso JC.

Mol Ther. 2011 Mar;19(3):500-6. doi: 10.1038/mt.2010.246. Epub 2010 Nov 16.

38.

A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection.

Uchida H, Chan J, Goins WF, Grandi P, Kumagai I, Cohen JB, Glorioso JC.

J Virol. 2010 Dec;84(23):12200-9. doi: 10.1128/JVI.01633-10. Epub 2010 Sep 22.

39.

Suppression of detrusor-sphincter dyssynergia by herpes simplex virus vector mediated gene delivery of glutamic acid decarboxylase in spinal cord injured rats.

Miyazato M, Sugaya K, Saito S, Chancellor MB, Goins WF, Goss JR, de Groat WC, Glorioso JC, Yoshimura N.

J Urol. 2010 Sep;184(3):1204-10. doi: 10.1016/j.juro.2010.04.066. Epub 2010 Jul 21.

40.

Equine herpesvirus type 1 (EHV-1) utilizes microtubules, dynein, and ROCK1 to productively infect cells.

Frampton AR Jr, Uchida H, von Einem J, Goins WF, Grandi P, Cohen JB, Osterrieder N, Glorioso JC.

Vet Microbiol. 2010 Feb 24;141(1-2):12-21. doi: 10.1016/j.vetmic.2009.07.035. Epub 2009 Aug 8.

41.

Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain.

Goins WF, Goss JR, Chancellor MB, de Groat WC, Glorioso JC, Yoshimura N.

Gene Ther. 2009 Apr;16(4):558-69. doi: 10.1038/gt.2009.19. Epub 2009 Feb 26.

42.

Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats.

Miyazato M, Sugaya K, Goins WF, Wolfe D, Goss JR, Chancellor MB, de Groat WC, Glorioso JC, Yoshimura N.

Gene Ther. 2009 May;16(5):660-8. doi: 10.1038/gt.2009.5. Epub 2009 Feb 19.

43.

Generation of herpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: resistance of HVEM-expressing cells and identification of mutations that rescue nectin-1 recognition.

Uchida H, Shah WA, Ozuer A, Frampton AR Jr, Goins WF, Grandi P, Cohen JB, Glorioso JC.

J Virol. 2009 Apr;83(7):2951-61. doi: 10.1128/JVI.01449-08. Epub 2009 Jan 7.

44.

Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin.

Yokoyama H, Sasaki K, Franks ME, Goins WF, Goss JR, de Groat WC, Glorioso JC, Chancellor MB, Yoshimura N.

Hum Gene Ther. 2009 Jan;20(1):63-71. doi: 10.1089/hum.2008.094.

45.

Construction and production of recombinant herpes simplex virus vectors.

Goins WF, Krisky DM, Wechuck JB, Huang S, Glorioso JC.

Methods Mol Biol. 2008;433:97-113. doi: 10.1007/978-1-59745-237-3_6.

PMID:
18679619
46.

Construction of replication-defective herpes simplex virus vectors.

Goins WF, Marconi P, Krisky D, Wolfe D, Glorioso JC, Ramakrishnan R, Fink DJ.

Curr Protoc Hum Genet. 2002 Aug;Chapter 12:Unit 12.11. doi: 10.1002/0471142905.hg1211s33.

PMID:
18428322
47.

Equine herpesvirus 1 enters cells by two different pathways, and infection requires the activation of the cellular kinase ROCK1.

Frampton AR Jr, Stolz DB, Uchida H, Goins WF, Cohen JB, Glorioso JC.

J Virol. 2007 Oct;81(20):10879-89. Epub 2007 Aug 1.

48.

Herpes simplex virus vector-mediated delivery of glial cell line-derived neurotrophic factor rescues erectile dysfunction following cavernous nerve injury.

Kato R, Wolfe D, Coyle CH, Huang S, Wechuck JB, Goins WF, Krisky DM, Tsukamoto T, Nelson JB, Glorioso JC, Chancellor MB, Yoshimura N.

Gene Ther. 2007 Sep;14(18):1344-52. Epub 2007 Jul 5.

PMID:
17611585
49.

Effect of temperature, medium composition, and cell passage on production of herpes-based viral vectors.

Wechuck JB, Ozuer A, Goins WF, Wolfe D, Oligino T, Glorioso JC, Ataai MM.

Biotechnol Bioeng. 2002 Jul 5;79(1):112-9.

PMID:
17590937
50.

Gene therapy applications for the treatment of neuropathic pain.

Goss JR, Goins WF, Glorioso JC.

Expert Rev Neurother. 2007 May;7(5):487-506. Review.

PMID:
17492900

Supplemental Content

Loading ...
Support Center